Clinical Psychopharmacology · Paper A
Antipsychotic-induced metabolic syndrome
Every antipsychotic changes brain chemistry to control psychosis: but some of that same chemistry quietly changes the body too, and knowing which specific drug carries the highest physical risk shapes both prescribing and monitoring. Imagine two patients started on different antipsychotics. Six months on, one has quietly gained significant weight and developed high blood sugar, while the other has stayed metabolically stable. Clinically, that difference usually comes down to which specific drug was chosen, not the fact that it's an antipsychotic at all.
Antipsychotic-induced metabolic syndrome is a cluster of three things happening together: central obesity (fat gathering around the waist), abnormal blood fats, and abnormal blood sugar. Two receptor effects drive it: blocking histamine H1 and serotonin 5-HT2C receptors increases appetite and drives weight gain, and separately, some antipsychotics blunt how well the body's cells respond to insulin, which is why blood sugar can rise even without weight gain. Risk isn't equal across drugs, because it tracks how strongly each drug hits those receptors. For example, olanzapine and clozapine bind them hardest and carry the highest risk across all three domains, quetiapine and risperidone bind them less strongly and carry intermediate risk, while aripiprazole's different receptor profile gives it the lowest risk of the group. In practice, this receptor-strength ordering is what should guide the choice of antipsychotic when metabolic risk is a concern.
Every antipsychotic drug changes brain chemistry to control psychosis, but the same receptor effects that calm psychotic symptoms can also disturb the body's metabolism. Metabolic syndrome (a cluster of central obesity, abnormal blood fats, and abnormal blood sugar occurring together) is a well-recognised complication of antipsychotic treatment. The risk is not a flat "antipsychotics cause weight gain" story: it differs sharply between individual drugs, and knowing which drug carries which risk is exactly what this topic tests.
Metabolic syndrome is a named cluster of physical findings, not just a vague sense that a patient has "put on weight." Two receptor mechanisms drive it. Blocking and serotonin 5-HT2C receptors increases appetite and drives weight gain, the most visible effect. Separately, some antipsychotics blunt insulin (how well the body's cells respond to insulin, the hormone that lowers blood sugar), which is why blood sugar can rise even in a patient who has not gained much weight at all.
The trap is treating "weight gain" as interchangeable with "metabolic syndrome," and treating all antipsychotics as if they carried the same risk. Neither is true. For example, imagine two patients started on different antipsychotics: six months later, one has gained significant weight and developed high blood sugar, while the other remains metabolically stable. That divergence usually reflects which specific drug was prescribed, not the mere fact of taking an antipsychotic.
Appetite and glucose control are regulated by different systems in the body, and antipsychotics can disrupt either one, or both, depending on their receptor profile. H1 and 5-HT2C blockade acts on appetite-regulating centres in the brain, driving overeating. Insulin resistance acts peripherally, on how muscle, fat, and liver tissue respond to insulin, and can develop through effects that are at least partly independent of weight gain. That is why a patient can develop dysglycaemia (abnormal blood sugar regulation) without first gaining obvious weight.
Risk tracks how strongly each drug binds the receptors responsible. Olanzapine and clozapine bind H1 and 5-HT2C receptors most strongly and carry the highest metabolic risk across all three domains: weight, lipids, and glucose. Quetiapine and risperidone bind these receptors less strongly and carry intermediate risk. Aripiprazole's different receptor profile, involving partial agonism (partially activating rather than simply blocking a receptor) rather than straightforward blockade, gives it the lowest metabolic risk of the group. This ordering should directly inform drug choice whenever metabolic risk is a clinical concern, such as in a patient who already has obesity or an existing glucose problem.
Two distinctions are easy to blur. First, antipsychotic-induced dysglycaemia arises from insulin resistance and direct effects on insulin signalling, not from autoimmune destruction of insulin-producing cells as in type 1 diabetes: this changes how it's investigated and managed, since it is treated first as a drug-related effect prompting a medication review, not purely as a new autoimmune diagnosis. Second, clozapine and olanzapine share the same highest-risk tier for metabolic syndrome, but clozapine carries an extra, unrelated monitoring requirement: mandatory full blood count testing to screen for agranulocytosis, a dangerous drop in a specific white blood cell type. Olanzapine has no equivalent requirement, and confusing these two monitoring pathways, metabolic versus haematological, is a common source of error.
The diagnosis of metabolic syndrome requires central obesity (increased waist circumference) plus at least two of four additional criteria: raised triglycerides, low HDL cholesterol, raised blood pressure, and raised fasting glucose. A patient with obesity alone, without meeting at least two of these further criteria, does not meet the diagnosis of metabolic syndrome, even though they may still be at elevated cardiovascular risk. This matters because meeting the full criteria carries a higher long-term risk of cardiovascular disease and type 2 diabetes than any single abnormal measurement alone. In practice, this diagnosis is established through the same parameters used for monitoring: weight, waist circumference, blood pressure, fasting glucose, and lipids, checked at baseline and then closely in the early weeks of treatment, when weight gain and metabolic change happen fastest.
The clinical logic is prevention-first: an antipsychotic's metabolic risk should shape the initial choice of drug, ongoing monitoring should catch problems early, and any deterioration should prompt a switch to a lower-risk agent as first-line management, rather than defaulting straight to additional medication for the resulting weight gain or dysglycaemia. This approach follows the Lester UK Adaptation, a physical health monitoring tool endorsed by NICE and widely used across Maudsley-affiliated psychiatric practice, which sets out exactly which parameters to check and when. Consider a patient started on olanzapine whose routine twelve-week physical health check picks up early weight gain and a rising fasting glucose. The correct response is to switch to a lower-risk antipsychotic, such as aripiprazole, as first-line management, before reaching for separate medications purely to treat the weight gain or blood sugar in isolation. If the presentation had progressed further, screening for other components of metabolic syndrome and referral for dedicated management of the abnormal glucose would then become necessary alongside the switch.
The high-yield trap is assuming every antipsychotic carries equal metabolic risk, or that any weight gain equals "metabolic syndrome." Remember the receptor-strength ordering (olanzapine and clozapine highest, quetiapine and risperidone intermediate, aripiprazole lowest), and remember that first-line management of an emerging metabolic problem is usually to switch the drug, not to add a new one to treat the side effect.
Antipsychotic metabolic risk tracks H1/5-HT2C receptor-binding strength and insulin-signalling disruption, is diagnosed by central obesity plus two of four further criteria, and is managed by early Lester-schedule monitoring with a switch to a lower-risk drug as the first move, not an add-on medication.